154 related articles for article (PubMed ID: 26993518)
21. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.
Malpica A; Deavers MT; Tornos C; Kurman RJ; Soslow R; Seidman JD; Munsell MF; Gaertner E; Frishberg D; Silva EG
Am J Surg Pathol; 2007 Aug; 31(8):1168-74. PubMed ID: 17667538
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients.
Battista MJ; Cotarelo C; Jakobi S; Steetskamp J; Makris G; Sicking I; Weyer V; Schmidt M
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1097-102. PubMed ID: 24728493
[TBL] [Abstract][Full Text] [Related]
24. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
25. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244
[TBL] [Abstract][Full Text] [Related]
26. Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
Dettmar L; Ahmed N; Kotzsch M; Diersch S; Napieralski R; Darmoul D; Schmitt M; Weichert W; Kiechle M; Dorn J; Magdolen V
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1109-1118. PubMed ID: 29546479
[TBL] [Abstract][Full Text] [Related]
27. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
28. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
Liao C; Wang A; Ma Y; Liu H
Medicine (Baltimore); 2021 Oct; 100(40):e27473. PubMed ID: 34622876
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
31. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer.
Alves MR; Do Amaral NS; Marchi FA; Silva FIB; Da Costa AABA; Carvalho KC; Baiocchi G; Soares FA; De Brot L; Rocha RM
Oncol Rep; 2019 Apr; 41(4):2254-2264. PubMed ID: 30720106
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
[TBL] [Abstract][Full Text] [Related]
34. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
35. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
[TBL] [Abstract][Full Text] [Related]
36. Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Surg Oncol; 2020 Aug; 122(2):315-319. PubMed ID: 32500598
[TBL] [Abstract][Full Text] [Related]
37. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
[TBL] [Abstract][Full Text] [Related]
38. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.
Bakkar R; Gershenson D; Fox P; Vu K; Zenali M; Silva E
Int J Gynecol Pathol; 2014 May; 33(3):302-8. PubMed ID: 24681743
[TBL] [Abstract][Full Text] [Related]
39. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
Lokman NA; Pyragius CE; Ruszkiewicz A; Oehler MK; Ricciardelli C
Transl Res; 2016 May; 171():83-95.e1-2. PubMed ID: 26925708
[TBL] [Abstract][Full Text] [Related]
40. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Chen X
Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
